This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): SI6603, chondroitinase ABC
Condoliase (SI-6603) is a formulation of the bacterial enzyme chondroitinase ABC for the treatment of lumbar disc herniation.
Chondroitinase degrades chondroitin sulfate proteoglycans (CSPGs) that inhibit axon regeneration after some forms of CNS damange.
Seikagaku and Kaken
In December 2015, Seikagaku Corporation and Kaken Pharmaceutical announced that they have concluded a basic distributor agreement concerning exclusive marketing rights in Japan for SI-6603 (condoliase). The agreement is based on the basic distributorship agreement executed on May 10, 2012.
Seikagaku and Ferring
In August 2016, Seikagaku Corporation and Ferring Pharmaceuticals announced that the companies have entered into an exclusive worldwide license agreement (excluding Japan) for SI-6603 (condoliase). The agreement is based on a letter of intent concluded on June 15, 2016.
Under the license agreement, Ferring acquires exclusive development and commercialization rights to SI-6603 worldwide, excluding Japan. Seikagaku will receive an upfront payment of US $5 million and milestone payments up to a maximum total amount of US $90 million over multiple years upon future progress in development and commercialization. Seikagaku is...See full deal structure in Biomedtracker
Partners: Seikagaku Corporation Kaken Pharmaceutical Company, Ltd
Additional information available to subscribers only: